Cadence Partners with Antiviral Discovery Consortium to Spearhead Rapid Development of Treatments for Viral Pandemics
07 Dezembro 2023 - 12:45PM
Business Wire
Antiviral Discovery Effort Funded by $68M NIH
Grant
Cadence Molecular Sciences (OpenEye)—a business unit of Cadence
Design Systems (Nasdaq: CDNS)—will provide OpenEye’s molecular
design software to power the open-science AI-driven
Structure-enabled Antiviral Platform (ASAP) Discovery Consortium in
support of an innovative effort to rapidly develop antivirals to
prevent future pandemics.
John D. Chodera, PhD, a lab head at the Memorial Sloan Kettering
Cancer Center (MSKCC), directs the researchers and software
scientists building the computational chemistry infrastructure to
support ASAP.
“Dr. Chodera and the ASAP scientists working with him will have
access to OpenEye tools to help support the ASAP Discovery
Consortium and antiviral drug research,” said Anthony Nicholls,
PhD, corporate vice president, OpenEye, Cadence Molecular Sciences.
“OpenEye’s software will aid in advancing therapeutics for
under-researched diseases and to prepare for pandemics.”
OpenEye’s Applications, Toolkits and Orion® platform—which
include ROCS®, FastROCS™, BROOD, OMEGA, OEChemTK, Grapheme™,
Nonequilibrium Switching (NES) Free Energy Calculations and other
tools—enable computational chemists working with the ASAP Discovery
Consortium to build a robust antiviral drug discovery pipeline
using technology, structural biology, artificial intelligence (AI),
machine learning and computational chemistry.
“Open-science drug discovery against future pandemics is an
essential public service,” said Chodera. “We are thrilled to have
access to OpenEye’s industry-leading software in this effort. The
OpenEye Toolkits have long been the backbone of our computer-aided
drug discovery infrastructure, and access to the Orion NES Free
Energy workflows allows us to run free energy calculations in mere
hours.”
The ASAP Discovery Consortium is an Antiviral Drug Discovery
(AViDD) U19 Center for Pathogens of Pandemic Concern funded by the
National Institute of Allergy and Infectious Diseases (NIAID), part
of the National Institutes of Health (NIH), via a $68 million grant
as part of the Antiviral Program for Pandemics (APP).
The NIH grant is for the initial three-year phase of the ASAP
Discovery Consortium, which aims to deliver multiple drug
candidates ready for evaluation in humans in the event of an
ongoing or emerging pandemic threat. The project will maximize the
use of an open science model that prioritizes global, equitable and
affordable access to antiviral medicine, generating a wealth of
antiviral data shared rapidly and openly.
ASAP builds on the successes of the COVID Moonshot, a global,
open-science collaboration that began in March 2020 and rapidly
identified potent antivirals targeting the main protease of the
SARS-CoV-2 virus. In July 2021, Moonshot received $11M in funding
from the Wellcome Trust to pursue an accelerated preclinical
program via the World Health Organization Access to COVID Tools
Accelerator (ACT-A) and is working with the Drugs for Neglected
Diseases Initiative (DNDi) to pursue clinical trials with a
straight-to-generics model.
The ASAP Discovery Consortium is led by PIs John Chodera
(MSKCC), Alpha Lee (PostEra) and Peter Sj� (DNDi). ASAP partners
include the Diamond Light Source (UK), the Weizmann Institute of
Science (Israel), Medchemica (UK), Mount Sinai (USA), the Stanford
University School of Medicine (USA) and the Fred Hutchinson Cancer
Center (USA), as well as a vast global network of scientists and
industry collaborators.
About ASAP
The AI-driven Structure-enabled Antiviral Platform (ASAP)
Discovery Consortium uses artificial intelligence and computational
chemistry to accelerate structure-based open-science antiviral drug
discovery and deliver oral antivirals for pandemics with the goal
of global, equitable and affordable access. For more information
about ASAP, including a complete list of diseases and drug targets
and all open data that it has generated, visit
https://asapdiscovery.org.
About Cadence
Cadence is a pivotal leader in electronic design, building upon
more than 30 years of computational software expertise. The company
applies its underlying Intelligent System Design™ strategy to
deliver software, hardware and IP that turn design concepts into
reality. Cadence® customers are the world’s most innovative
companies, delivering extraordinary electronic products from chips
to boards to systems for the most dynamic market applications,
including consumer, hyperscale computing, 5G communications,
automotive, mobile, aerospace, industrial and healthcare. For nine
years in a row, Fortune magazine has named Cadence one of the 100
Best Companies to Work For. Learn more at www.cadence.com.
Category: Featured
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231207130587/en/
Cadence Newsroom 408-944-7039 newsroom@cadence.com
Cadence Design Systems (NASDAQ:CDNS)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Cadence Design Systems (NASDAQ:CDNS)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024